The earnings call highlighted Bausch + Lomb's strong revenue growth across segments, successful product launches, and substantial innovation in their R&D pipeline. Despite challenges from currency headwinds and the Inflation Reduction Act, the company maintains a positive outlook with strategic investments in key products and technologies. The sentiment is largely positive with a focus on sustained growth and innovation.

Company Guidance

During the Bausch + Lomb Fourth Quarter 2024 earnings call, the company provided robust financial guidance for 2025, highlighting a revenue range of $4.95 billion to $5.05 billion, which reflects constant currency growth of approximately 5.5% to 7.5%. The adjusted EBITDA is projected between $900 million and $950 million, excluding any potential one-time in-process research and development charges. The company anticipates an adjusted gross margin of approximately 62.5% and plans to invest around 7.5% of revenue in R&D. Despite potential headwinds from currency fluctuations, estimated to impact revenue by $100 million and adjusted EBITDA by $20 million, Bausch + Lomb remains optimistic about sustained growth across all segments. The guidance also accounts for a $25 million impact from the Inflation Reduction Act, with expectations for the highest revenue in the fourth quarter.

Strong Revenue Growth

Achieved 17% constant currency revenue growth for the year with five straight quarters of double-digit growth. Contact lens revenue grew 13% for Q4 and 11% for the full year, with Daily SiHy lenses reporting over 70% growth.

Successful Product Launches

Miebo exceeded expectations with $172 million in revenue. Xiidra reached $364 million in full-year revenue. LUMIFY saw 24% revenue growth in Q4.

Innovation and R&D Overhaul

Overhauled R&D organization, developing new biomimetic contact lenses and myopia control solutions. Revamped pharma pipeline with upcoming novel treatments for eye health.

Strong Segment Performance

All three reporting segments delivered double-digit constant currency revenue growth. Vision Care revenue increased by 11%, Surgical by 15%, and Pharma by 7% for Q4.

Positive Financial Metrics

Adjusted gross margin for the full year was 62.6%, up 160 basis points. Adjusted EBITDA grew by 20% versus 2023. Adjusted cash flow from operations was $263 million for the full year compared to $56 million in 2023.

---

Bausch + Lomb Corporation (BLCO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BLCO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 30, 2025	2025 (Q1)	0.04 / -	0.07	―	―	―
Feb 19, 2025	2024 (Q4)	0.23 / 0.25	0.24	4.17% (+0.01)
Oct 30, 2024	2024 (Q3)	0.16 / 0.17	0.22	-22.73% (-0.05)
Jul 31, 2024	2024 (Q2)	0.13 / 0.13	0.18	-27.78% (-0.05)
May 01, 2024	2024 (Q1)	0.07 / 0.07	0.1	-30.00% (-0.03)
Feb 21, 2024	2023 (Q4)	0.17 / 0.24	0.23	4.35% (<+0.01)
Nov 01, 2023	2023 (Q3)	0.19 / 0.22	0.31	-29.03% (-0.09)
Aug 02, 2023	2023 (Q2)	0.15 / 0.18	0.29	-37.93% (-0.11)
May 03, 2023	2023 (Q1)	0.14 / 0.10	0.24	-58.33% (-0.14)
Feb 22, 2023	2022 (Q4)	0.22 / 0.23	0.39	-41.03% (-0.16)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

BLCO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 19, 2025	$16.35	$16.30	-0.31%
Oct 30, 2024	$20.76	$20.44	-1.54%
Jul 31, 2024	$16.87	$17.22	+2.07%
May 01, 2024	$14.54	$13.74	-5.50%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---